The Epoch Times
By
March 11, 2022 Updated: March 11, 2022
Pfizer plans to ask U.S. regulators to grant emergency use authorization for a second booster of its COVID-19 vaccine, CEO Albert Bourla said March 11.
“Clearly there is a need in an environment of Omicron to boost the immune response,” Bourla said on CNBC’s “Squawk Box.”
Pfizer’s vaccine waned over time in protection against both infection and hospitalization when the Delta variant of the virus that causes COVID-19 was dominant in the United States, real-world data and studies showed. The issue has grown more pronounced since Omicron displaced Delta in late 2021.